• Home/
  • Bionano U/
  • Bionano mapping outperforms existing clinical tests in Duchenne’s Muscular Dystrophy patients

In a publication in Genome Medicine, a team of researchers from Children’s National Health Center (CNHC) and the University of California, Los Angeles (UCLA) led by Dr. Eric Vilain report the first molecular diagnoses of patients with genetic disease using Bionano genome mapping.

The scientists used Bionano Irys and Saphyr systems to identify pathogenic structural variants in a series of patients diagnosed with Duchenne muscular dystrophy (DMD), caused by large deletions, insertions, and inversions disrupting the X-linked dystrophin gene. DMD is a severe degenerative muscle disorder mostly affecting boys, for which there is currently no cure.

In this study, Dr. Vilain’s team identified both single and multiple exon deletions up to 250 Kbp in size, a 13 Kbp duplication, and a 5.1 Mbp inversion all disrupting the dystrophin gene of study patients. Large structural variants of this size are typically detected with poor sensitivity using NGS or long-read sequencing. They also successfully identified the carrier status in mothers of the patients. The patient with the large inversion had been diagnosed with DMD through an invasive muscle biopsy, after chromosomal microarray, MLPA, PCR sequencing of all 79 exons, and exome sequencing all failed to detect the pathogenic inversion.

In the paper, the authors state enthusiastically that Bionano mapping “has the capacity to replace both MLPA and chromosomal microarrays in the clinical setting.” MLPA is a probe-based assay to detect the deletion or duplication of specific loci in the genome. For this study, the authors cite as key advantages over MLPA, Bionano’s ability to also provide order and orientation of structural variants and the ability to detect these variants genome wide. Compared to chromosomal microarray, Dr. Vilain’s team discusses Bionano’s capability to detect balanced events such as inversions and balanced translocations, as well as much smaller variations completely missed by microarray. Relative to NGS, the authors state that Bionano provides higher sensitivity for large structural variants with better false-positive and false-negative rates. Turnaround time and cost are comparable to the aforementioned tests.
The study concludes that Bionano mapping “is poised to become a new tool in the clinical genetic diagnostic strategy and research due to its ability to sensitively identify large genomic variations.”

Bionano’s CEO Dr. Erik Holmlin is equally enthusiastic about this publication:  “We are excited by Dr. Vilain’s team demonstrating Bionano’s ability to correctly identify structural variants in patients with genetic disease. The current diagnostic process proves to be a true odyssey for many of the children and parents hoping to find answers or treatment. Dr. Vilain shows that in some cases a single Bionano test could replace or outperform up to four different tests, which would not only simplify testing, but would also dramatically shorten the search for answers. We are also happy with the illustration in this work of how Bionano provides translational researchers with a tool that sees genome variations that other technologies miss. We can’t wait to see how other scientists and physicians, inspired by these incredible results, use Bionano mapping in their genome studies and analyses.”

Have a look at a story on this paper in GEN, in Muscular Dystrophy News Today, or on the PLoS Blog. The study is published in issue (2017) 9:90 of Genome Medicine.

Top

This website stores cookies on your computer. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Privacy Policy.